<DOC>
	<DOCNO>NCT01220544</DOCNO>
	<brief_summary>Experimental clinical data suggest alloreactive NK cell reduce risk graft-rejection , GvHD leukemic relapse HLA-mismatched transplantation . The effectiveness allogeneic NK cell function HLA-differences donor recipient give rise NK cell clone express inhibitory receptor match HLA molecule recipient . Aim study evaluate cellular therapy alloreactive , IL-2 activate NK cell transplantation T-cell deplete stem cell graft one haplotype mismatch family donor patient hematological malignancy .</brief_summary>
	<brief_title>Haploidentical Transplantation With Early Adoptive Transfer CD56+CD3- NK Cells</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients AML ALL first CR follow high risk feature : 1 . AML aberration Del ( 5q ) 5 , del ( 7q ) 7 , ( 9 ; 22 ) ( 6 ; 9 ) , abn 3q , 9q , 11q , 20q , 21q , 17p ; 2 . AML complex caryotype ; 3. secondary AML previous chemo radiotherapy MDS ; 4 . Phpositive ALL Patients AML ALL induction failure second CR Patients CML second chronic accelerate phase Patients malignant Lymphoma follow high risk feature : 1. relapse autologous transplantation 2. primary chemotherapy refractory disease All patient must fulfill follow criterion : 1. lack suitable HLAidentical family , unrelated cord blood donor 2. active infection , severe impairment cardial , pulmonary , renal hepatic function 3. blast count marrow &lt; 30 % 4. informed consent active infection , severe impairment cardial , pulmonary , renal hepatic function blast count marrow &gt; 30 % unable unwilling sign and/or understand inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>